Kirkland advised J.P. Morgan Private Capital on the final closing of its inaugural biotechnology venture capital fund, 270 Life Sciences Private Capital Fund I. The fund closed above its $500 million target, attracting strong support from investors, including institutional allocators, strategic corporate partners, family offices and high net worth individuals across North America, Europe, the Middle East and Asia. The fund invests in private biotechnology companies across stage, modality,…
Read More…